We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-6.57%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$992B
AUM Growth
-$120B
Cap. Flow
-$16.9B
Cap. Flow %
-1.7%
Top 10 Hldgs %
27.94%
Holding
3,085
New
108
Increased
1,637
Reduced
1,059
Closed
107

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$4.45B
2
JPM icon
JPMorgan Chase
JPM
+$2.22B
3
TEAM icon
Atlassian
TEAM
+$2.08B
4
NVDA icon
NVIDIA
NVDA
+$1.81B
5
AAPL icon
Apple
AAPL
+$1.67B

Sector Composition

Rank Sector Weight
1 Technology 26.79%
2 Healthcare 17.19%
3 Consumer Discretionary 15.16%
4 Financials 10.74%
5 Communication Services 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
AVAH icon
2851
Aveanna Healthcare
AVAH
$1.97B
$91K ﹤0.01%
26,632
+1,000
+4% +$5.43K
RMTI icon
2852
Rockwell Medical
RMTI
$29.6M
$91K ﹤0.01%
1,746
-671
-28% -$28.4K
LAB icon
2853
Standard BioTools
LAB
$312M
$89K ﹤0.01%
24,661
+1,900
+8% +$6.56K
QNCX icon
2854
Quince Therapeutics
QNCX
$31.8M
$89K ﹤0.01%
72
-7
-9% -$9.53K
NVVE
2855
DELISTED
Nuvve Holding Corp
NVVE
0
DARE icon
2856
Dare Bioscience
DARE
$21.6M
$87K ﹤0.01%
+4,883
New +$92.3K
TCRT icon
2857
Alaunos Therapeutics
TCRT
$4.88M
$86K ﹤0.01%
879
+119
+16% +$15.3K
AIXC
2858
AIxCrypto Holdings Inc
AIXC
$15M
$85K ﹤0.01%
258
-51
-17% -$19.9K
TAL icon
2859
TAL Education Group
TAL
$6.58B
$85K ﹤0.01%
28,200
STXS icon
2860
Stereotaxis
STXS
$139M
$83K ﹤0.01%
22,376
+5,721
+34% +$27K
IVC
2861
DELISTED
Invacare Corporation
IVC
$82K ﹤0.01%
58,257
-16,600
-22% -$35.5K
APT icon
2862
Alpha Pro Tech
APT
$54.8M
$81K ﹤0.01%
19,400
+1,300
+7% +$6.04K
EZRA
2863
Reliance Global Group
EZRA
$1.93M
$80K ﹤0.01%
+2
New +$123K
ESPR
2864
DELISTED
Esperion Therapeutics
ESPR
$79K ﹤0.01%
+17,091
New +$73.3K
PRPL icon
2865
Purple Innovation
PRPL
$28.4M
$79K ﹤0.01%
542
+44
+9% +$8.66K
TONX
2866
TON Strategy Co
TONX
$158M
$79K ﹤0.01%
10
+3
+43% +$28K
ME
2867
DELISTED
23andMe Holding Co
ME
$79K ﹤0.01%
1,030
WYY icon
2868
WidePoint Corp
WYY
$114M
$78K ﹤0.01%
20,700
KULR icon
2869
KULR Technology Group
KULR
$137M
$76K ﹤0.01%
4,388
-1,400
-24% -$26K
LTRX icon
2870
Lantronix
LTRX
$275M
$75K ﹤0.01%
11,200
OPAD icon
2871
Offerpad Solutions
OPAD
$22.5M
$75K ﹤0.01%
+100
New +$68K
RFL icon
2872
Rafael Holdings
RFL
$103M
$75K ﹤0.01%
30,350
SRGA
2873
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$75K ﹤0.01%
8,223
LIDR icon
2874
AEye
LIDR
$61.4M
$74K ﹤0.01%
+450
New +$51.6K
DHT icon
2875
DHT Holdings
DHT
$3.01B
$73K ﹤0.01%
+12,616
New +$69.5K

Similar funds

T. Rowe Price Associates's Q1 2022 Portfolio in Review

As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
  • T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
  • T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
  • T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
  • T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
  • T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.